Racura Oncology Ltd RAC
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- A$1.82
- Day Range
- A$1.76–1.85
- 52-Week Range
- A$1.76–4.90
- Bid/Ask
- A$1.76 / A$1.82
- Shares Outstanding
- 196.07M
- Market Cap
- A$345.08M
- Volume/Avg
- 55,732 / 78,859
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Racura Oncology Ltd is a Phase 3 clinical-stage biopharmaceutical company with a dedicated mission to silence cancer. The company's clinical programs include the Phase 3 EMILI trial in acute myeloid leukaemia, the Phase 1a/b HARNESS trial in combination with osimertinib for EGFR-mutated non-small cell lung cancer, and the Phase 1a/b CPACS trial in combination with doxorubicin, where it aims to deliver both anthracycline cardioprotection and enhanced anticancer activity. The company operated in two segments, being research into an oncology drug, RC220, and the manufacturing and distribution of the drug for clinical trials.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- —
- Website
- https://www.racuraoncology.com
Valuation
|
Metric
|
RAC
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 9.47 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
RAC
Financial Strength
|
Metric
|
RAC
|
|---|---|
Quick Ratio | 21.28 |
Current Ratio | 21.43 |
Interest Coverage | — |
Quick Ratio
RAC
Profitability
|
Metric
|
RAC
|
|---|---|
Return on Assets (Normalized) | −37.01% |
Return on Equity (Normalized) | −39.12% |
Return on Invested Capital (Normalized) | −41.54% |
Return on Assets
RAC
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|?$VQtwH | LOCK|!nv^Y | $129B | |||
| Moderna Inc
MRNA
| LOCK|%#n?%T | LOCK|!m$ | $90B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|?!L&%cz | LOCK|Sd%yy | $77B | |||
| argenx SE ADR
ARGX
| LOCK|>c<^Qz | LOCK|wK | $51B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|>L&@>^ | LOCK|$< | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|HyBS!G | LOCK|z!Kx | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|#jfY@?< | LOCK|@nzQ | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|G<$>hC | LOCK|@M | $24B | |||
| Incyte Corp
INCY
| LOCK|l<XCMc | LOCK|h@? | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|%H&!>G | LOCK|@h | $14B |
United States